Corriere della Sera

Corriere della Sera dedicates its issue “Speciale Salute” to the CVBF and its efforts in the fields of Rare diseases and Paediatrics

On March 1st, 2015 the national newspaper Corriere della Sera published, on its special issue Sezione Salute, an article entirely dedicated to CVBF and its contributions and goals in the fields of rare diseases and paediatrics. The article, entitled “Rare diseases and Paediatrics: the goals of the Consorzio per Valutazioni Biologiche e Farmacologiche – Clinical Trial, development of new methodologies and innovative drugs”, is an interview to Donato Bonifazi (CVBF Managing Director), who has outlined the main areas of interest and the activities undertaken by CVBF. Among the activities and the European initiatives coordinated by the Consortium in the field of the paediatric clinical research, a particular emphasis is given to the two European projects DEEP (DEferiprone Evaluation in Paediatrics) and GAPP (GAbapentin in Paediatric Pain) and the efforts made by both the European and non-European Countries of the Mediterranean area. In this respect, explained Dr. Bonifazi, a special attention is given to Albania, for potentials that this country offers in clinical research (and especially in paediatrics). […]

2017-01-03T11:18:10+00:00 03/03/2015|Categories: News & Events, Press Releases|Tags: , , , |

CVBF – Towards new frontiers of paediatric clinical research

On February 27th, 2015, the national newspaper Corriere della Sera  has published on its section “Corriere Sociale,” dedicated to volunteering and Third Sector, an article on CVBF and its activities in the field of rare diseases and paediatrics. The page describes the four main focus areas of the Consortium: Clinical Trials  (promotion of an ethical use of medication, ethics and regulatory counselling, organisation and conduction of clinical trials, pharmacovigilance services, CRO and CME providers activities and drug management), Regulatory Consultancy  (whose value lies in the set of competencies guaranteed by the consortium members), Scientific Research  (in particular paediatric clinical research, conducted in the context of European projects), Training  (with particular regard to the DEEP project and its significant contribution in the field of paediatric research, with the aim of making the iron chelating agent deferiprone- DFP, available in a new formulation specifically tested for children with β-thalassaemia and other transfusion dependent haemoglobinopathies). Here you can download the complete article.

2017-01-03T11:18:10+00:00 03/03/2015|Categories: News & Events, Press Releases, Press Review|Tags: , |